News | April 27, 2010

Key Trial Data Explained at SCAI's Annual Meeting

The Society for Cardiovascular Angiography and Interventions’ (SCAI) upcoming 33rd Annual Scientific Sessions promises the latest news in interventional cardiology from leading experts in the field. The event will take place May 5-8 in San Diego.

This year’s meeting will feature a late-breaking clinical trial surrounding two-year interim results from the single-arm study of the Zilver PTX drug-eluting peripheral stent. William Gray, M.D., will present the data at 11:30 a.m. Pacific time on Friday, May 7.

Additionally, the following notable abstracts will be presented at the meeting:

• One-year results from the EVEREST II High Risk Registry, which examines the safety and efficacy of the transcatheter MitraClip Therapy in relieving symptoms for patients with mitral regurgitation.

• Safety and efficacy data from the ARMOUR trial — a pivotal, prospective, multicenter, nonrandomized trial to evaluate the safety and effectiveness of cerebral protection with the Mo.Ma embolic protection device in high surgical risk subjects undergoing carotid artery stenting (CAS).

• Early findings from the first clinical human study designed to investigate an implantable ST-segment monitoring system that detects and alerts patients to coronary plaque rupture and ischemia.

• Results surrounding the impact of a seven day, 24-hour in-hospital cardiac catheterization lab program on door-to-balloon time in patients presenting with ST-elevated myocardial infarction (STEMI) during off verses regular hours.

• Retrospective review of patients undergoing percutaneous coronary intervention (PCI) and same-day discharge, compared for their appropriateness under the 2009 the American College of Cardiology/American Heart Association/SCAI guidelines on outpatient PCI.

• Hypotheses surrounding the low rate of adoption of transradial access (TRA) for cardiac catheterization in the United States.

Other meeting highlights include a session surrounding practice survival in the era of health care reform, led by Gregory J. Dehmer, M.D., and Edward T. Fry, M.D. Keynote addresses will cover the influence of comparative effectiveness on interventional cardiology; the past, present, and future of stent treatment for congenital heart disease; and a historical perspective of the early days of coronary intervention.

The inauguration of Larry S. Dean, M.D., FSCAI, FACC, FAHA as 33rd president of SCAI will also take place during the annual meeting. Dean recently played an integral role in communicating concerns to the Washington State Health Technology Assessment Committee regarding its proposal to restrict coverage of drug-eluting stents for state-insured employees and Medicaid beneficiaries.

For more information: www.scai.org

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Overlay Init